Influence of TLS Risk and Patient Preferences on Treatment Selection in Relapsed/Refractory CLL

Author(s):

Nitin Jain, MD,Joanna M. Rhodes, MD, MSCE

Panelists discuss how they evaluate patients for tumor lysis syndrome (TLS) risk, considering factors such as tumor burden, renal function, and prior therapies, and how this assessment influences their decision between prescribing a non-covalent BTK inhibitor or a venetoclax-based regimen for chronic lymphocytic leukemia treatment.

EP: 1.The Current Treatment Landscape for R/R CLL

EP: 2.Impact of Prior BTKi vs BCL2i Therapy on Treatment Decision-Making in CLL

EP: 3.Key Patient-Specific Factors Guiding Treatment Selection in CLL

EP: 4.Tailoring Treatment Approaches for Rapid vs. Slow Disease Progression in CLL

EP: 5.Assessing Resistance to First-Line BTK Inhibitor Therapy: The Emergine Role of Testing in CLL

EP: 6.Pirtobrutinib in the Management of R/R CLL: Updates from the BRUIN Trial

EP: 7.Application of Pirtobrutinib in R/R CLL: Expert Perspectives

Now Viewing

EP: 8.Influence of TLS Risk and Patient Preferences on Treatment Selection in Relapsed/Refractory CLL

EP: 9.Navigating treatment strategies for patients with multi-refractory CLL: CAR-T, ASCT, and PI3K Inhibitors

EP: 10.Sequencing and Combination Strategies with Pirtobrutinib and CAR-T Therapy in R/R CLL

EP: 11.Treatment Sequencing in Relapsed/Refractory CLL: Key Factors Influencing Decision-Making

EP: 12.Emerging role of doublet triplet therapies in R/R CLL: Expert Perspectives

EP: 13.The Impact of Emerging Resistance Patterns on Treatment Sequencing in R/R CLL

EP: 14.Multidisciplinary Approach to Managing Treatment for Relapsed/Refractory CLL

Video content above is prompted by the following:

How do you assess patients for potential risk of TLS? How does this impact your treatment choice for a non-covalent BTKi over a venetoclax-based regimen?